

HR 1188

FLAT Prices Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 13, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 14, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/1188>

Sponsor

Name: Rep. Golden, Jared F. [D-ME-2]

Party: Democratic • State: ME • Chamber: House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Casten, Sean [D-IL-6]	D · IL		Feb 13, 2019
Rep. Cisneros, Gilbert Ray, Jr. [D-CA-39]	D · CA		Feb 13, 2019
Rep. Pingree, Chellie [D-ME-1]	D · ME		Feb 13, 2019
Rep. Rose, Max [D-NY-11]	D · NY		Feb 13, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Feb 13, 2019
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Jun 6, 2019
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Oct 31, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 14, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 366	Identical bill	Feb 6, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S921-922)

Forcing Limits on Abusive and Tumultuous Prices or the FLAT Prices Act

This bill directs the Food and Drug Administration to reduce the market exclusivity of an approved prescription drug if the drug manufacturer increases the drug's price by more than a specified percentage. This reduction may be waived under specified circumstances.

Actions Timeline

- **Feb 14, 2019:** Referred to the Subcommittee on Health.
- **Feb 13, 2019:** Introduced in House
- **Feb 13, 2019:** Referred to the House Committee on Energy and Commerce.